InnSight Technology, Inc. specializes in advanced point-of-care diagnostics, particularly through its innovative OcuCheck™ Biosensor. This device is designed for precise tear fluid analysis, enabling the quantitative measurement of specific biomarkers such as MMP-9 and Lacritin. The OcuCheck stands out as the only device capable of simultaneously measuring MMP-9 and tear film osmolarity, making it a critical tool for diagnosing and managing dry eye disease. Its lightweight and portable design allows for use in various settings, enhancing accessibility to diagnostic services.

The company's focus extends beyond dry eye diagnostics, as it aims to leverage its platform technology to detect biomarkers for systemic diseases. InnSight Technology is committed to translational research that bridges laboratory innovations with clinical practice, thereby improving personalized medicine. By providing objective measurements of tear fluid biomarkers, the company seeks to standardize treatment solutions and enhance the overall quality of care for patients suffering from both ocular and systemic conditions.

United States

The OcuCheck is a point-of-care device that uses a specialized electrical chemical sensor with proprietary coatings to measure specific biomarkers in the tear film Currently, the OcuCheck is the only device that can simultaneously measure MMP-9 and tear film osmolarity in one device. It is also one of the most accurate devices for quantitative measurement of MMP-9.

InnSight Technology, Inc

Company Details